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Future Perspectives of the Sentinel Node Concept: Implications for
Clinical Trials
SPL Leong
Department of Surgery, Univeristy of California, San Francisco, USA
In human solid cancers, lymph node status is the most important prognostic
indicator of clinical outcome. Recent developments in the sentinel lymph node
(SLN) concept and technology have resulted in the application of this revolutionary
procedure to define the first draining node or SLN to which the cancer will
metastasize. Selective sentinel lymphadenectomy (SSL) should be considered a
standard of care for staging patients with primary invasive melanoma 1 mm or
greater. It is essential that multidisciplinary teams should master the techniques of
preoperative lymphoscintigraphy, intraoperative lymphatic mapping, and patholo-
gic evaluation of the SLNs. The prognosis of micrometastasis in SLNs remains to be
defined. Whether a complete lymph node dissection should be done following a
positive SLN will be addressed by the ongoing multicenter selective sentinel
lymphadenectomy trial (MSLT II). There is evidence that significant immunosup-
pression may be present in the SLNs. CCL21 in the regional lymph nodes regulates
the recruitment of T cells, NK cells and dendritic cells. Recent studies have shown
that tumor cells can bear chemokine receptors and may facilitate tumor metastasis.
The critical issue to be defined is the role of the SLN in the process of lymphatic
metastasis. Clinical trials using immune adjuvants such as GM-CSF may be
developed to reverse immunosuppression in the SLNs with resultant expectation to
eliminate micrometastosis in the SLNs.
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Proteomics & Genomics: Concepts for Side Studies
D Schadendorf
Skin Cancer Unit, German Cancer Research Center & University Hospital
Mannheim, Germany
A better understanding of all biological and genetic events has led recently to the
development of more targeted treatment modalities. New techniques open new
avenues in diagnosis and treatment of cancer patients. In parallel translational
research on patient material donated while on studies will drive the way for a
further improvement of pathogenetic understanding, the definition of risk groups as
well as the identification of profiles associated with chemical characterization such
as response to treatment or biology of the disease. All these new markers and
concepts need to be validated prospectively in large multi-center trials before there
will be a routine standard.
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Sorafenib, a Pluripotent Molecule
SS Agarwala
Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, USA
One of the major targets under investigation for anticancer targeted therapies is the
Ras mediated pathway which plays a central role in a variety of signal transduction
processes. Downstream of Ras, the Raf serine/threonine kinases have emerged as
the principal effectors of Ras in the mitogen-activated protein kinase (MAPK)
pathway. This pathway has been the focus of considerable attention recently
because of disappointing effects of therapy directed at Ras, particularly with the
farnesyltransferase inhibitors. The Raf family consists of three genes A-raf, B-raf and
C-raf. B-raf mutations have emerged as an important therapeutic target in
melanoma particularly because b-raf mutations have been demonstrated in
60%–70% of melanomas and an even higher frequency of as much as 80% in
benign nevi. The major mutation in B-raf, previously known as V599E now known
as V600E, is caused by a thymidine to adenine transversion at nucleotide position
1796 in exon 11 or 15. Sorafenib is a small molecule Raf inhibitor previously
known as BAY 43-9006 and is furthest along in clinical development in this class of
drugs. It is a bi-aryl urea and potently inhibits activation of the MAPK pathway and
ERK phosphorylation in human cancer cell lines. It is also a potent inhibitor of
various receptor targeted kinases that are involved in tumor progression and
angiogenesis including VEGFR-2, VEGFR-3 and platelet-derived growth factor.
Phase I studies established a dose of 400 mg administered orally twice a day as the
recommended phase II dose based upon dose related toxicities of diarrhea, skin
rash, fatigue, hypertension and a hand-food syndrome. Development of sorafenib
has been unique in that because of the likelihood that this agent would produce
stable disease and improvement in time-to-progression as opposed to a response,
the principal trial design selected was a randomized discontinuation design. The
major disease to have benefited in those early studies was renal cell carcinoma.
This drug is now approved for that indication. Phase I studies were also done in
combination with carboplatin and paclitaxel which demonstrated unexpectedly
high activity in metastatic melanoma. Based upon this Flaherty and colleagues
performed a phase II evaluation of sorafenib with carboplatin and paclitaxel in
patients with metastatic melanoma and have shown results that appear to be
promising with an overall 36% response rate and a median time-to-progression of
8.8 months. Based upon this randomized clinical trials are underway both in the
first line and second line setting for patients with metastatic melanoma testing the
combination of carboplatin and paclitaxel with sorafenib or with placebo in an
effort to improve survival and time to progression.
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Antiangiogenic Strategies: Current Trials
J Gille
Department of Dermatology, Johann Wolfgang Goethe-University, Frankfurt a.M.,
Germany
Antiangiogenic cancer therapy has been frequently perceived as ‘‘magic bullet’’,
capable to eventually cure any type of cancer. This unrealistic perception was
largely based on overwhelming preclinical experiences with first generation
antiangiogenic agents. Realistically, however, the goal of antiangiogenic cancer
therapy is to inhibit the tumor’s capacity to grow beyond considerable size. Hence,
angiogenesis inhibitors are primarily expected to halt tumor progression and to
induce disease stabilization. While sole inhibition of vascular endothelial growth
factor (VEGF)-driven angiogenesis failed to increase survival in most advanced
cancer patients, targeting VEGF in combination with standard chemotherapies has
finally proved successful in prolonging overall survival of different types of
metastatic cancer compared with standard chemotherapy alone. While simulta-
neous targeting of both vascular and cancer cells was mainly achieved by
combining anti-VEGF monoclonal antibody bevacizumab with standard cytotoxic
therapies, multitargeted small molecule tyrosine kinase inhibitors (TKIs) alone may
increase survival of cancer patients, as they can affect pathways involved in both
endothelial and cancer cell survival and/or growth. A variety of different clinical
trials have been recently imitated in advanced melanoma patients that evaluate the
impact of targeted antiangiogenic therapy by using bevacizumab and multitargeted
TKIs (e.g., sorafenib, AZD2171), either alone or in combination with cytotoxic
chemotherapy. The opportunities and obstacles of combinatorial growth factor-
and growth factor receptor-targeted antiangiogenic approaches for malignant
melanoma will be herein discussed with particular reference to selected ongoing
clinical trials. In this regard, the development of broadspectrum TKIs constitutes a
crucial strategy to delay or minimize resistance to antiangiogenic agents, as
antiangiogenic TKIs may exert distinct complementary mechanisms of action that
target also signaling of angiogenic molecules other than VEGF and affect both
endothelial cells and other proangiogenic cell populations. Angiogenesis inhibitors
are likely to change cancer therapies in the next decade; however, future standard
treatment of cancers can be anticipated to still rely on the combinatorial use of
conventional cytotoxic and/or cancer-directed targeted therapies.
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Thymosin-Alpha: A New Immunomodulator
K Peris and MC Fargnoli
Department of Dermatology, University of L’Aquila, L’Aquila, Italy
Thymosin alpha-1 (Talpha1) is a 28-amino acid polypeptide, produced syntheti-
cally but originally isolated from thymosin fraction 5, a bovine thymus extract
containing a number of immunologically active peptides. It has multiple biological
activities primarily directed towards immune response enhancement: in vitro
studies have shown that Talpha1 can influence T-cell maturation and differentia-
tion, stimulate production of Th1 cytokines such as IFNalpha and IL-2, and activate
natural killer cell-mediated cytotoxicity. Talpha1 has been evaluated for its
immunomodulatory activities and related therapeutic potential in infectious
diseases and cancer. As a biologic response modifier, Talpha1 is clinically used
in combination with IFNalpha for patients with chronic hepatitis virus B and C
infection showing significant virological and biochemical response rates and being
well tolerated. It is believed to be useful to prevent liver cirrhosis and
hepatocarcinoma related to chronic viral hepatitis. In clinical trials, the addition
of Talpha1 to combination chemoimmunotherapy regimens has resulted in
significant improvement in response and survival times in different cancers such
as lung cancer, melanoma, leukemia, squamous cell carcinoma, colon cancer.
Finally, Talpha1 has also been shown to be helpful for reducing the adverse effects,
mainly hematological toxicity, of cytotoxic drug therapy in neoplastic patients.
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Selective Electrochemical Tumour Ablation (SECTA) with Intralesional
Bleomycin
P Radny1, C Garbe2, L Bruckner-Tuderman1 and D Nashan1
1Department of Dermatology, University of Freiburg, Germany and
2Department of Dermatology, University of Tu¨bingen, Germany
To date, there is no recommended standard therapy for recurrent and inoperable
tumours of skin and soft tissue. While su!rgery, cryotherapy, radiotherapy, systemic
or intratumoral immuno-/ chemotherapy, are commonly used, management of skin
and soft tissue tumours can be a major challenge, particularly in cases of rapidly
progressive disease, and multiple recurrences. Intralesional therapy modalities
typically lack severe side effects and can be desirable alternatives. The therapeutic
value of several intralesionally administered cytostatic agents and cytokines, such
as bleomycin, cisplatin, interferon-alfa, fotemustine, interferon-beta, GM-CSF and
IL-2 has been investigated with varying outcomes. SECTA delivers promising and
out-standing results. SECTA is a novel treatment, using pulsed electrical currents,
which enable the delivery of large molecules such as bleomycin into cells. The
efficacy and feasibility of this new treatment option has been reported for head and
neck tumours, various types of skin cancer, notably in malignant melanoma.
Depending on localisation and general health of patients, treatments were
administered on an outpatient basis or they were hospitalization for 1-3 days;
patients tolerated treatment well and objective response rates appear higher than
with other therapies, including intralesional bleomycin alone. To substantiate
SECTA in combination with intralesionally administered bleomycin, a prospective,
multicenter pre-marketing clinical trial for the treatment of cutaneous cancer is
currently being conducted at 19 centres through-out Europe. SECTA is an effective,
outpatient based, well-tolerated and minimally therapeutic option for patients
presenting with cutaneous and soft tissue tumours.
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